Home › Gastrointestinal Stromal Tumors › Illinois › Chicago
Gastrointestinal Stromal Tumors clinical trials in Chicago, IL
4 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Chicago
- GSK Investigational Site, Chicago
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
RecruitingPhase 2
- University of Chicago Medical Center, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RecruitingPhase 3
- Northwestern University, Chicago
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
RecruitingPhase 1
- Northwestern University, Chicago
Gastrointestinal Stromal Tumors trials in other cities
- Miami, FL8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Houston, TX6 studies
- Philadelphia, PA6 studies
- Portland, OR5 studies
- San Diego, CA5 studies
- Nashville, TN5 studies
- Omaha, NE5 studies
- Jacksonville, FL4 studies
- Dallas, TX4 studies
- Durham, NC4 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer59 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Lung Cancer41 studies
- Obesity41 studies
- Ovarian Cancer36 studies
- Colorectal Cancer34 studies
- Stroke34 studies
- Heart Failure31 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.